'Smoking Cessation - Data, Analysis & Forecasts to 2023' published by GMR Data’

Oct. 25, 2013 - PRLog -- GMR Data’s new pharmaceutical report outlines the factors affecting the global smoking cessation market across the forecast period 2013-2023. The report outlines key drivers and restraints of the market in all key global geographies.

Drivers include;

Increased health care / health education in many geographies

Adoption of smoking cessation products onto health insurance policies

Increasing number of smoking cessation products emerging onto the market

Emergence of e-cigarettes onto the global market

Over 1bn smokers world wide

GMR Data’s 'Smoking Cessation - Data, Analysis & Forecasts to 2023'report quantifies the market, in terms of each key geography; explaining which direction each key market will head across the next ten years, and why, with detailed financial forecasts. The report contains over 110 pages as well as over 85 charts, graphs and tables detailing the market.

This report also breaks down the market in terms of current smoking cessation drugs and products that occupy the market at present; examining the key prescription and OTC drugs that drive the market. In addition to this crucial information this report offers analysis and opinion on current R&D in the smoking cessation sector alongside in depth analysis of the emerging, global e-cigarette market. How will e-cigarettes affect the traditional smoking cessation market place? When will the FDA & EU drug agencies make a decision on the efficacy of these new entrants on the market?

This report also includes 3 original, exclusive, interview transcripts with key global pharmaceutical companies;

Pfizer

Elder Pharmaceuticals

GlaxoSmithKline

For further details and a free sample of this report, please follow; http://gmrdata.com/pharmaceutical-reports/the-global-smoking-cessation-market-2013-2023.html

For further information regarding this, or any other GMR Data report, please contact info@gmrdata.com

Table of contents
Chapter 1 Executive Summary

1.1.          Smoking Cessation Market Review

1.2.          Chapter Breakdown

1.3.          Research and Analysis Methods

Chapter 2 Introduction to Smoking Cessation

2.1          Smoking Cessation Treatment Overview

2.1.1         Nicotine Replacement Therapy (NRT)

2.1.2        Non-NRT Therapy

2.2          Global Tobacco Consumption Prevalence, Trends & Impact

2.2.1        Prevalence of Death Caused due to Tobacco

2.2.2       Second-Hand Smoking

2.2.3       Increased Awareness of Health Implications in Relation to Smoking

2.2.4       Tobacco Advertising Bans

2.2.5       Increased Taxation

Chapter 3 Smoking Cessation Market Forecasts

3.1          Global Smoking Cessation Market

3.1.1    Global NRT Market

3.1.2        Global Smoking Cessation Prescription Drugs Market

Chapter 4 Key Global Smoking Cessation Markets 2013-2023

4.1          The US Smoking Cessation Market

4.2          The UK Smoking Cessation Market

4.3          The France Smoking Cessation Market

4.4          The German Smoking Cessation Market

4.5          The Spanish Smoking Cessation Market

4.6          The Italian Smoking Cessation Market

4.7          The Japanese Smoking Cessation Market

4.8        The Rest of World Smoking Cessation Market

Chapter 5 Nicotine Replacement Therapies (NRT) Market

5.1          NicoDerm CQ

5.2      Nicotrol

5.3      Habitrol (Nicotinell)

5.4          Nicorette

Chapter 6 Prescription Drugs Smoking Cessation Market

6.1          Chantix (by Pfizer): Varenicline

6.2          Zyban / Wellbutrin (by GSK): Bupropion

Chapter 7 Leading Companies in the Global Smoking Cessation Market

7.1          Pfizer

7.2          GlaxoSmithKline (GSK)

7.3          Novartis

7.4          Johnson & Johnson (J&J)

7.5          Perrigo

7.6          Sophomore and Extab

7.7          22nd Century Group, Inc.

Chapter 8 SWOT Analysis of the Smoking Cessation Market

8.1          Strengths

8.1.1         FDA Relaxation in the NRT Market

8.1.2         Increased Insurance Cover for Smoking Cessation Products

8.1.3     Strong Mature Markets

8.2          Weaknesses

8.2.1       Weak R&D pipeline for the smoking cessation market

8.2.2      Side Effects to Current Drugs/Therapies on the Market

8.3          Opportunities

8.3.1       E-cigarettes

   8.3.1.1.  E-cigarettes Legal Status

   8.3.1.2.  E-cigarettes background

   8.3.1.3. Geographic Breakdown & Market Share for E-cigarettes

   8.3.1.4 Market Forecast

   8.3.1.5 E-cigarette Industry Regulation

8.3.2      Future Research on Drugs/Therapies Currently on the Market

8.3.3      Strong Emerging Markets

8.4          Threats

8.4.1 Pool of Smokers Greatly Reduced in Some Key Markets

8.4.2 New Drug / Product threat

Chapter 9 Expert Opinion

9.1          Pfizer

9.2          Elder Pharmaceuticals

9.3          GlaxoSmithKline